Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takuya Osada

Showing results (101-110 of 132) with videos related to

Pageof 14
Sort By:
Immunotherapy|June 14, 2019
Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growthYuanyuan Sun, Suya Wang, Hainan Yang, et al.
The Journal of Clinical Investigation|August 4, 2010
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerMichael A Morse, Amy C Hobeika, Takuya Osada, et al.
Journal for Immunotherapy of Cancer|November 12, 2020
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratioErika J Crosby, Amy C Hobeika, Donna Niedzwiecki, et al.
Breast Cancer Research : BCR|August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancersTakuya Osada, Zachary C Hartman, Junping Wei, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2012
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effectsTakuya Osada, Peter Berglund, Michael A Morse, et al.
Oncoimmunology|July 7, 2017
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibitionTakuya Osada, Michael A Morse, Amy Hobeika, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Case Reports in Oncology|August 15, 2024
Enfortumab Vedotin-Induced Febrile Neutropenia and Hyperglycemia Successfully Treated with Multidisciplinary Treatment Including Continuous Hemodialysis Filtration and Insulin Injection in a Patient with Chemo-Resistant Metastatic Urothelial Carcinoma: A Case ReportAyatsugu Otsuka, Norifumi Sawada, Ryosuke Suda, et al.
Cancer Science|November 8, 2005
Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancerTakeshi Tsuchiya, Yurai Okaji, Nelson H Tsuno, et al.
Journal of Translational Medicine|February 23, 2005
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancerMichael A Morse, Jennifer Garst, Takuya Osada, et al.
Pageof 14

Showing results (101-110 of 132) with videos related to

Sort By:
Pageof 14
Immunotherapy|June 14, 2019
Impact of synchronized anti-PD-1 with Ad-CEA vaccination on inhibition of colon cancer growthYuanyuan Sun, Suya Wang, Hainan Yang, et al.
The Journal of Clinical Investigation|August 4, 2010
An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancerMichael A Morse, Amy C Hobeika, Takuya Osada, et al.
Journal for Immunotherapy of Cancer|November 12, 2020
Long-term survival of patients with stage III colon cancer treated with VRP-CEA(6D), an alphavirus vector that increases the CD8+ effector memory T cell to Treg ratioErika J Crosby, Amy C Hobeika, Donna Niedzwiecki, et al.
Breast Cancer Research : BCR|August 11, 2018
Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancersTakuya Osada, Zachary C Hartman, Junping Wei, et al.
Cancer Immunology, Immunotherapy : CII|April 11, 2012
Co-delivery of antigen and IL-12 by Venezuelan equine encephalitis virus replicon particles enhances antigen-specific immune responses and antitumor effectsTakuya Osada, Peter Berglund, Michael A Morse, et al.
Oncoimmunology|July 7, 2017
Vaccination targeting human HER3 alters the phenotype of infiltrating T cells and responses to immune checkpoint inhibitionTakuya Osada, Michael A Morse, Amy Hobeika, et al.
Breast Cancer Research : BCR|September 19, 2013
An heregulin-EGFR-HER3 autocrine signaling axis can mediate acquired lapatinib resistance in HER2+ breast cancer modelsWenle Xia, Emanual F Petricoin, Sumin Zhao, et al.
Case Reports in Oncology|August 15, 2024
Enfortumab Vedotin-Induced Febrile Neutropenia and Hyperglycemia Successfully Treated with Multidisciplinary Treatment Including Continuous Hemodialysis Filtration and Insulin Injection in a Patient with Chemo-Resistant Metastatic Urothelial Carcinoma: A Case ReportAyatsugu Otsuka, Norifumi Sawada, Ryosuke Suda, et al.
Cancer Science|November 8, 2005
Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancerTakeshi Tsuchiya, Yurai Okaji, Nelson H Tsuno, et al.
Journal of Translational Medicine|February 23, 2005
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancerMichael A Morse, Jennifer Garst, Takuya Osada, et al.
Pageof 14